Prime Medicine (PRME) said late Wednesday it priced a public offering of 38 million common shares at $3.30 each for about $125.4 million in expected gross proceeds.
Underwriters have a 30-day overallotment option to buy up to 5.7 million additional shares. The company said the underwriters will not receive discounts or commissions for 1.8 million shares sold to the Cystic Fibrosis Foundation.
The offering is expected to close Friday.
Prime Medicine shares were down 8.4% in recent premarket activity Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.